EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,

Caroline Robert, Brian Gastman, Helen Gogas, Piotr Rutkowski, Georgina V Long, Marya F Chaney, Harshada Joshi, Yu-Lin Lin, Wendy Snyder, Jason A Chesney

European Journal of Cancer · 2024-08 · 207 · 114120

DOI: 10.1016/j.ejca.2024.114120 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024-08. Verfasst von Caroline Robert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy and Paris-Saclay University, Villejuif, France. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized, Biological Products, Herpesvirus 1, Human. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntibodies, Monoclonal, HumanizedBiological ProductsHerpesvirus 1, HumanHumansMaleMiddle AgedFemaleAgedAdultImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAged, 80 and overSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsOncolytic VirotherapyAntineoplastic Agents, ImmunologicalDisease Progression

Stichwörter der Autor:innen

ImmunotherapyMelanomaOncolytic virusProgrammed cell death-1

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanizedtalimogene laherparepvecBiological ProductsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
  • National and Kapodistrian University of Athens, Athens, Greece.
  • Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, New South Wales, Australia.
  • Merck & Co., Inc., Rahway, NJ, USA.

Förderung

  • Amgen

Zitieren

APA

Robert, C., Gastman, B., Gogas, H., Rutkowski, P., Long, G. V., Chaney, M. F., Joshi, H., Lin, Y. L., Snyder, W., & Chesney, J. A. (2024). Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,. European Journal of Cancer, 207, 114120. https://doi.org/10.1016/j.ejca.2024.114120

Vancouver

Robert C, Gastman B, Gogas H, Rutkowski P, Long GV, Chaney MF, et al. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,. European Journal of Cancer. 2024;207:114120. doi:10.1016/j.ejca.2024.114120

BibTeX
@article{Robert2024,
  author = {Robert, Caroline and Gastman, Brian and Gogas, Helen and Rutkowski, Piotr and Long, Georgina V and Chaney, Marya F and Joshi, Harshada and Lin, Yu-Lin and Snyder, Wendy and Chesney, Jason A},
  title = {Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {207},
  pages = {114120},
  doi = {10.1016/j.ejca.2024.114120}
}
Kostenlos starten →